The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

The Oncodetect test is a highly sensitive, tumor-informed assay that empowers oncologists and patients with critical insights ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with ...

Exact Sciences is down 9.1% during the same time and is heading into earnings with an average analyst price target of $72.19 (compared to the current share price of $49.31).

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ...

“Exact Sciences is proud to be recognized as a Great Place To Work for the seventh year in a row—an honor that reflects the passion, integrity, and drive for innovation of our incredible team,” said ...

Exact Sciences Corporation (EXAS) reported robust financial and operational performance in its third-quarter 2024 earnings. With record revenue, improved EBITDA, and significant pipeline ...

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive ...

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive ...